BR112019008402A2 - cápsula compósita e método para preparar a cápsula compósita - Google Patents
cápsula compósita e método para preparar a cápsula compósitaInfo
- Publication number
- BR112019008402A2 BR112019008402A2 BR112019008402A BR112019008402A BR112019008402A2 BR 112019008402 A2 BR112019008402 A2 BR 112019008402A2 BR 112019008402 A BR112019008402 A BR 112019008402A BR 112019008402 A BR112019008402 A BR 112019008402A BR 112019008402 A2 BR112019008402 A2 BR 112019008402A2
- Authority
- BR
- Brazil
- Prior art keywords
- coating layer
- layer formed
- core
- composite capsule
- methacrylic acid
- Prior art date
Links
- 239000002775 capsule Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 239000002131 composite material Substances 0.000 title 2
- 239000010410 layer Substances 0.000 abstract 6
- 239000011247 coating layer Substances 0.000 abstract 4
- 239000002702 enteric coating Substances 0.000 abstract 4
- 238000009505 enteric coating Methods 0.000 abstract 4
- 229920003145 methacrylic acid copolymer Polymers 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000011248 coating agent Substances 0.000 abstract 2
- 238000000576 coating method Methods 0.000 abstract 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 abstract 2
- 229960004770 esomeprazole Drugs 0.000 abstract 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
um aspecto da presente invenção fornece uma cápsula complexa e um método de preparação para a mesma, em que a cápsula complexa compreende uma primeira parte de dissolução que compreende: um núcleo que contém, como um ingrediente ativo, esomeprazol ou um sal farmaceuticamente aceitável do mesmo; uma camada de revestimento interno formada no núcleo; e uma primeira camada de revestimento entérico formada na camada de revestimento interno, e uma segunda parte de dissolução que compreende: um núcleo que contém, como um ingrediente ativo, esomeprazol ou um sal farmaceuticamente aceitável do mesmo; uma camada de revestimento interno formada no núcleo; e uma segunda camada de revestimento entérico formada na camada de revestimento interno, em que a primeira camada de revestimento entérico compreende, como uma base de revestimento, um copolímero de ácido metacrílico ld em uma quantidade de 5 a 50% (p/p) do núcleo que tem a camada de revestimento interno formada no mesmo, e a segunda camada de revestimento entérico compreende, como uma base de revestimento, uma mistura de 1,5:1 a 3,5:1 (p/p) de um copolímero de ácido metacrílico s e um copolímero de ácido metacrílico l em uma quantidade de 15 a 40% (p/p) do núcleo que tem a camada de revestimento interno formada no mesmo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160142156A KR101877350B1 (ko) | 2016-10-28 | 2016-10-28 | 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법 |
| PCT/KR2017/011571 WO2018080104A1 (ko) | 2016-10-28 | 2017-10-19 | 에스오메프라졸 함유 복합 캡슐제 및 그 제조방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019008402A2 true BR112019008402A2 (pt) | 2019-07-09 |
Family
ID=62023771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008402A BR112019008402A2 (pt) | 2016-10-28 | 2017-10-19 | cápsula compósita e método para preparar a cápsula compósita |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11052048B2 (pt) |
| EP (1) | EP3513784A4 (pt) |
| JP (1) | JP2019532960A (pt) |
| KR (1) | KR101877350B1 (pt) |
| CN (1) | CN109890372B (pt) |
| AU (1) | AU2017349091A1 (pt) |
| BR (1) | BR112019008402A2 (pt) |
| EA (1) | EA201990704A1 (pt) |
| MX (1) | MX2019004938A (pt) |
| PH (1) | PH12019500919A1 (pt) |
| WO (1) | WO2018080104A1 (pt) |
| ZA (1) | ZA201902867B (pt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200368219A1 (en) * | 2017-09-28 | 2020-11-26 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition including multi-unit spheroidal tablet containing esomeprazole and spheroidal pharmaceutically acceptable salt thereof, and method of preparing the pharmaceutical composition |
| CN113597302A (zh) * | 2019-04-02 | 2021-11-02 | 韩美药品株式会社 | 一种包括埃索美拉唑或其药学上可接受的盐并具有双重释放特性的药物组合物 |
| KR102312604B1 (ko) * | 2020-02-04 | 2021-10-15 | 한국유나이티드제약 주식회사 | 장용성의 프로톤펌프억제제 및 서방성의 모사프리드 제제를 포함하는 경질캡슐 제제 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1078628T3 (da) | 1994-07-08 | 2009-02-23 | Astrazeneca Ab | Tabletteret flerenhedsdoseringsform |
| MY148805A (en) * | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| NZ544608A (en) | 2003-07-17 | 2008-07-31 | Reddys Lab Ltd Dr | Pharmaceutical compositions having a swellable coating comprising prolamin |
| WO2005051362A2 (en) * | 2003-11-28 | 2005-06-09 | Ranbaxy Laboratories Limited | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating |
| AR052225A1 (es) | 2004-11-04 | 2007-03-07 | Astrazeneca Ab | Formulaciones de tabletas de liberacion modificada par inhibidores de la bomba de protones |
| EP2319504A1 (en) * | 2009-11-07 | 2011-05-11 | Laboratorios Del. Dr. Esteve, S.A. | Pharmaceutical solid dosage form |
| WO2012001705A2 (en) * | 2010-06-29 | 2012-01-05 | Cadila Healthcare Limited | Pharmaceutical compositions of (r)-lansoprazole |
| CN102100671B (zh) * | 2011-01-14 | 2013-04-24 | 寿光富康制药有限公司 | 一种埃索美拉唑镁肠溶微丸的制备方法 |
| CN102670521B (zh) * | 2012-05-18 | 2014-05-21 | 珠海润都制药股份有限公司 | 一种埃索美拉唑镁肠溶微丸及其制备方法 |
| CN102940611B (zh) * | 2012-11-26 | 2017-02-22 | 康普药业股份有限公司 | 一种含有埃索美拉唑镁的肠溶片剂 |
| CN103040774B (zh) * | 2012-11-30 | 2015-03-04 | 上海信谊万象药业股份有限公司 | 埃索美拉唑镁肠溶片中埃索美拉唑镁的制粒包衣工艺 |
| CN104940170A (zh) * | 2015-07-23 | 2015-09-30 | 浙江亚太药业股份有限公司 | 一种埃索美拉唑镁肠溶胶囊及其制备方法 |
-
2016
- 2016-10-28 KR KR1020160142156A patent/KR101877350B1/ko active IP Right Grant
-
2017
- 2017-10-19 BR BR112019008402A patent/BR112019008402A2/pt active Search and Examination
- 2017-10-19 CN CN201780067122.4A patent/CN109890372B/zh active Active
- 2017-10-19 US US16/345,456 patent/US11052048B2/en active Active
- 2017-10-19 AU AU2017349091A patent/AU2017349091A1/en not_active Abandoned
- 2017-10-19 EP EP17866143.5A patent/EP3513784A4/en active Pending
- 2017-10-19 WO PCT/KR2017/011571 patent/WO2018080104A1/ko unknown
- 2017-10-19 EA EA201990704A patent/EA201990704A1/ru unknown
- 2017-10-19 MX MX2019004938A patent/MX2019004938A/es unknown
- 2017-10-19 JP JP2019519729A patent/JP2019532960A/ja not_active Ceased
-
2019
- 2019-04-24 PH PH12019500919A patent/PH12019500919A1/en unknown
- 2019-05-07 ZA ZA2019/02867A patent/ZA201902867B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3513784A1 (en) | 2019-07-24 |
| EA201990704A1 (ru) | 2019-09-30 |
| PH12019500919A1 (en) | 2019-08-19 |
| WO2018080104A1 (ko) | 2018-05-03 |
| EP3513784A4 (en) | 2020-06-03 |
| KR101877350B1 (ko) | 2018-08-09 |
| JP2019532960A (ja) | 2019-11-14 |
| US11052048B2 (en) | 2021-07-06 |
| MX2019004938A (es) | 2019-10-09 |
| CN109890372B (zh) | 2022-06-24 |
| CN109890372A (zh) | 2019-06-14 |
| ZA201902867B (en) | 2020-08-26 |
| KR20180046682A (ko) | 2018-05-09 |
| AU2017349091A1 (en) | 2019-05-16 |
| US20190247316A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| BR112019008402A2 (pt) | cápsula compósita e método para preparar a cápsula compósita | |
| CO2019005729A2 (es) | Preparación de complejos sólidos de ciclodextrina para suministro de ingredientes farmacéuticos activos oftálmicos | |
| MX2021010359A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| BR112015022972A2 (pt) | composição farmacêutica de cloridrato de s-cetamina | |
| BR112019005046A2 (pt) | combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk | |
| BR112013017302A2 (pt) | formulações de imunossupressor | |
| BR112017028468A2 (pt) | formulação sólida oral, e método para preparar uma formulação sólida oral | |
| BR112014016472A8 (pt) | formulação farmacêutica estável para administração oral que compreende levocetirizina ou um sal farmaceuticamente aceitável da mesma e montelukast ou um sal farmaceuticamente aceitável do mesmo | |
| BR112015023481A8 (pt) | projeto de perfil de liberação de fármaco de controle via composição de lipossomo em ambos os compartimentos aquosos e não-aquosos | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| BR112018009413A2 (pt) | formulação oral sólida e método para preparar a formulação oral sólida | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112018074434A2 (pt) | composições farmacêuticas compreendendo safinamida | |
| BR112018073556A2 (pt) | medicamento e composição farmacêutica para a prevenção ou o tratamento da neuralgia trigeminal, método para prevenir ou tratar neuralgia trigeminal em um indivíduo, e, uso de um composto de carbamato . | |
| AR097202A1 (es) | Composiciones farmacéuticas de ranolazina y dronedarona, procedimiento para elaborar tableta bicapa | |
| BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112014032264A8 (pt) | Composiçâo para tratamento ou prevençâo de doenças relacionadas á permeabilidade vascular, contendo imatinibe ou um sal farmaceuticamente aceitável respectivo como ingrediente ativo | |
| CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
| BR112021005192A8 (pt) | Processo para a preparação de uma forma de dosagem oral de múltiplas unidades de liberação modificada de succinato de doxilamina e cloridrato de piridoxina | |
| BR112022016626A2 (pt) | Preparado farmacêutico | |
| BR112012024346A2 (pt) | agente terapêutico ou agente profilático para a doença de alzheimer | |
| MX2021000769A (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. | |
| MX2019005005A (es) | Tableta de liberacion extendida que comprende un farmaco de perdida de peso. | |
| EA201691763A1 (ru) | Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |